Login to Pancreatic Cancer UK

Our General Election Manifesto

Before the last General Election on the 8th June 2017, we have launched our General Election Manifesto, calling on the next government to commit to changing the story for pancreatic cancer patients, so people with the disease live a better, longer life.

Changing the story for pancreatic cancer

With pancreatic cancer set to become the fourth biggest cancer killer by 2026, we desperately need the government to commit to improving care and survival outcomes now.

We called on parliamentarians to change the story for pancreatic cancer patients by:

  • Our current relationship with the European Union provides the UK with access to research funding and expertise, as well as ongoing clinical trials.  The next government must consider the impact of these benefits on pancreatic cancer patients and families as we embark on a new chapter in Britain’s history. #ResearchAtRisk

  • There is an urgent need for more pancreatic cancer research. Progress needs to be made across the board, especially those projects focusing on early diagnosis, the development of new drugs and treatments and personalised medicine. Unless we tackle these and other vital research challenges we stand no long-term hope of improving survival or ensuring that everyone diagnosed with pancreatic cancer has the chance to live as long and as good a life as possible.

  • Pancreatic cancer patients in the UK desperately need better access to new effective treatments on the NHS to help them improve the quality and length of their lives.  This means reforming the way treatments are assessed. In particular, we are calling for the National Institute of Health and Care Excellence (NICE) to factor in the relative survival gain offered by new drugs for cancers with extremely poor survival rates, like pancreatic cancer. The NICE appraisal system should take into account much broader measures of quality of life and other potential benefits of new treatments to cancer patients, rather than just focusing on costs and clinical benefits as recorded in a trial setting.  See our Key to Survival campaign for more. 

  • To tackle this disease, the next government must support and provide funding for early diagnosis initiatives. Public Awareness campaigns about pancreatic cancer symptoms and increased education for healthcare professionals about pancreatic cancer and the electronic tools that assess cancer risk help everyone recognise the signs and symptoms of pancreatic cancer before it is too late.  Meanwhile, faster and improved pathways to diagnosis and treatment (including GP access to CT scans and patient access to one-stop clinics and faster referrals) ensure that patients do not waste valuable time ping-ponging between professionals and tests waiting for a diagnosis. See our Raise Awareness work for more.

  • Cancer patient experience surveys across the UK have consistently shown that the care received by pancreatic cancer patients often falls short of expected standards Although pancreatic cancer is the 11th most common cancer in the UK, national survey responses by pancreatic cancer patients were  low.  The length of time taken to prepare and send the questionnaires and poor prognosis of the disease means that many patients have already passed away before they are able to participate in the survey. The next government must strive to understand and improve the standard of care pancreatic cancer patients receive.  Instituting faster survey delivery, better and more robust collection systems, and benchmarking, will help us better evaluate and improve pancreatic cancer patients’ experiences, especially surrounding diagnosis and overall care.   See our Patient Charter to find out about the standard of care all 

  • The next government must support the implementation of England’s Cancer Strategy, “Achieving World Class Outcomes: A Strategy for England 2015-2020.” This should include a focus on ensuring that the Cancer Strategy delivers improvements for less survivable cancers. In particular, the successful implementation of recommendations on patient experience, increased diagnostic capacity and diagnostic targets can change the story for pancreatic cancer patients.